Patient-derived tumor organoids with p53 mutations, and not wild-type p53, are sensitive to synergistic combination PARP inhibitor treatment

Autor: Madorsky Rowdo, Florencia P., Xiao, Gu, Khramtsova, Galina F., Nguyen, John, Martini, Rachel, Stonaker, Brian, Boateng, Richard, Oppong, Joseph K., Adjei, Ernest K., Awuah, Baffour, Kyei, Ishmael, Aitpillah, Frances S., Adinku, Michael O., Ankomah, Kwasi, Osei-Bonsu, Ernest B., Gyan, Kofi K., Altorki, Nasser K., Cheng, Esther, Ginter, Paula S., Hoda, Syed, Newman, Lisa, Elemento, Olivier, Olopade, Olufunmilayo I., Davis, Melissa B., Martin, M. Laura, Bargonetti, Jill
Zdroj: In Cancer Letters 1 March 2024 584
Databáze: ScienceDirect
Externí odkaz: